[1] Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol,2020,18(12):2650-2666.
[2] Mezzano G, Juanola A, Cardenas A.Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gut,2022,71(1):148-155.
[3] Bajaj JS, O'Leary JG, Lai JC, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol,2022,117(2):225-252.
[4] Arroyo V, Angeli P, Moreau R. Investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif). The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol,2021,74(3):670-685.
[5] Chakraborty RK, Burns B. Systemic inflammatory response syndrome. in: statpearls. Treasure Island (FL): StatPearls Publishing,May 30, 2022.
[6] Borgonovo A, Baldin C, Maggi DC, et al. Systemic inflammatory response syndrome in patients hospitalized for acute decompensation of cirrhosis. Can J Gastroenterol Hepatol,2021,2021:5581587. Published 2021 Apr 25.
[7] Kim JH, Jun BG, Lee M, et al. Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study. Clin Mol Hepatol,2022,28(3):540-552.
[8] Trebicka J, Amoros A. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis. Front Immunol,2019,10:476.
[9] Trebicka J, Fernandez J, Papp M.Predict study group of the EASL-CLIF Consortium. The predict study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol,2020,73(4):842-854.
[10] Fernández J, Acevedo J. European Foundation for the Study of Chronic Liver Failure. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut,2018,67(10):1870-1880.
[11] 利振坤,何吕芬,李欢.慢加急性肝衰竭并发侵袭性真菌感染患者临床特点及其影响因素分析.实用肝脏病杂志,2021,24(4):520-523.
[12] Casulleras M, Zhang IW, López-Vicario C.Systemic inflammation and immunopathology in acute-on-chronic liver failure. Cells,2020,9(12):2632.
[13] Bruneau A, Hundertmark J, Guillot A, et al. Molecular and cellular mediators of the gut-liver axis in the progression of liver diseases. Front Med (Lausanne),2021,8:725390.
[14] Li Q, Wang J, Lu M, et al. Acute-on-chronic liver failure from chronic-hepatitis-b, who is the behind scenes. Front Microbiol,2020,11:583423.
[15] Engelmann C, Sheikh M, Sharma S, et al. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. J Hepatol,2020,73(1):102-112.
[16] Engelmann C, Habtesion A, Hassan M, et al. Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. J Hepatol,2022,S0168-8278(22)02939-7.
[17] Zeng Y, Li Y, Xu Z, et al. Myeloid-derived suppressor cells expansion is closely associated with disease severity and progression in HBV-related acute-on-chronic liver failure. J Med Virol, 2019,91(8):1510-1518.
[18] Li J, Liang X, Jiang J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF. Gut, 2022,71(1):163-175.
[19] Alcaraz-Quiles J, Titos E, Casulleras M, et al. Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure. Hepatology,2017,65(1):202-216.
[20] Schaapman JJ, Amoros À, van der Reijden JJ, et al. Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection. Liver Int,2020,40(3):646-653.
[21] Zhang Y, Wu W, Wang Y, et al. Gene profiling of Toll-like receptor signalling pathways in neutrophils of patients with acute-on-chronic liver failure. J Transl Med,2021,19(1):465.
[22] Engelmann C, Clària J, Szabo G. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol,2021,75 Suppl 1(Suppl 1):S49-S66.
[23] Jia Y, Ma L, Wang Y, et al. NLRP3 inflammasome and related cytokines reflect the immune status of patients with HBV-ACLF. Mol Immunol,2020,120:179-186.
[24] 杨燕,葛斐林,黄倩.核苷酸结合寡聚化结构域样受体蛋白3炎性小体在肝脏疾病中的作用机制.临床肝胆病杂志,2022,38(4):942-946.
[25] Bera C, Wong F. Management of hepatorenal syndrome in liver cirrhosis: a recent update. Therap Adv Gastroenterol,2022,15:17562848221102679.
[26] Gupta K, Bhurwal A, Law C, et al. Acute kidney injury and hepatorenal syndrome in cirrhosis. World J Gastroenterol,2021,27(26):3984-4003.
[27] Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology,2019,157(1):149-162.
[28] Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology,2021,74(2):1014-1048.
[29] Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med,2021,384(9):818-828.
[30] Kulkarni AV, Ravikumar ST, Tevethia H, et al. Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study. Sci Rep,2022,12(1):5503. Published 2022 Apr 1.
[31] Li C, Wang W, Xie SS, et al. The programmed cell death of macrophages, endothelial cells, and tubular epithelial cells in Sepsis-AKI. Front Med (Lausanne),2021,8:796724.
[32] Allegretti AS. Acute kidney injury treatment in decompensated cirrhosis: a focus on kidney replacement therapy. Kidney Med,2020,3(1):12-14.
[33] Moreau R, Clària J, Aguilar F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol,2020,72(4):688-701.
[34] Zaccherini G, Aguilar F, Caraceni P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. J Hepatol,2021,74(5):1117-1131.
[35] Jiménez C, Ventura-Cots M, Sala M, et al. Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH). Liver Int,2022,42(5):1109-1120.
[36] Shokravi S, Borisov V, Zaman BA, et al. Mesenchymal stromal cells (MSCs) and their exosome in acute liver failure (ALF): a comprehensive review. Stem Cell Res Ther,2022,13(1):192. |
